AURORA
34 evidence topics · 10 sources
Objective
Primary objective: proportion of MG-ADL responders at Month 4
Study purpose and population: adults with AChR antibody-positive generalized myasthenia gravis
Location and study date
Registry study dates and recruitment status, September 2026 record
“Study Start (Actual) 2025-05-06” (opens the source at this quote in a new tab)
“Primary Completion (Estimated) 2026-12-30” (opens the source at this quote in a new tab)
“Study Completion (Estimated) 2027-09-30” (opens the source at this quote in a new tab)
“Last Update Posted 2026-09-01” (opens the source at this quote in a new tab)
Trial initiation: company statement
Registry site count and site locations by country
European Union member states, start of trial, and recruitment end dates
Estimated primary completion, March 2026 record, superseded in August 2026
Study design
Randomized, double-blind, placebo-controlled, multicenter phase 3 design
One-to-one randomization to six once-weekly outpatient infusions without preconditioning chemotherapy
Two study parts: double-blind Part 1 and open-label Part 2
Masked dosing and follow-up to Month 4, then optional Descartes-08 infusions: company trial schema
FDA Special Protocol Assessment agreement on the trial design, January 2025
Eligibility criteria
Age, disease classification, and MG-ADL threshold
Background immunosuppressive therapy and corticosteroid dose
Exclusions for disease duration, treatment history, and other neuromuscular disease
Washout periods for IVIg, plasma exchange, B-cell depleting agents, FcRn antagonists, and complement inhibitors
Infection, immunodeficiency, malignancy, and vaccination exclusions
Treatment
Descartes-08 arm: leukapheresis and manufactured autologous mRNA CAR T-cell therapy
Placebo arm: infusion without Descartes-08
Six weekly masked doses of Descartes-08 or placebo: company trial schema
Study outcomes
Rationale for using MG-ADL response as the primary endpoint
Primary endpoint: MG-ADL improvement of 3 points or more at Month 4 compared with placebo
Secondary endpoints: safety, MGC improvement of 4 points or more, QMG, and MG-QoL-15r
Secondary endpoints at Month 4 and over 1 year: company trial schema
MG-ADL instrument and its use as a primary endpoint in trials
“The Myasthenia Gravis Activities of Living (MG‐ADL) scale is an 8‐item patient‐reported scale that measures myasthenia gravis (MG) symptoms and functional status.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of trials beginning in 2018 or later, 46.7% (n = 7) have used the MG‐ADL as a primary outcome compared to 10.0% (n = 2) of trials prior to 2018 (Figure 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sensitivity and specificity of 1-point and 3-point MG-ADL changes, and responder thresholds used in trials
“In this study, results from sensitivity and specificity analyses indicated that a 1‐point change in MG‐ADL was highly sensitive (96%) but did not have good specificity (71%), and a 3‐point change had good specificity (90%) but was not very sensitive (62%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of these 13 studies, 53.8% (n = 7) used a 2‐point improvement only, 30.8% (n = 4) used a 3‐point improvement only, 7.6% (n = 1) showed results for improvements ranging from 2 to 8 points, and 7.6% (n = 1) did not report how an MG‐ADL responder was defined.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A 2‐point responder threshold has been established in the mild to moderate MG population, but further research is needed to determine the appropriate responder threshold for a severe MG population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Precedent for a 3-point MG-ADL responder definition: REGAIN and the eculizumab label
“Results from the REGAIN trial showed that increasing the stringency of the responder definition at week 26 with higher thresholds revealed a more substantial difference between eculizumab and placebo (3‐point MG‐ADL improvement: 60% eculizumab responders, 40% placebo responders, P = .0229; 5‐point MG‐ADL improvement: 45% eculizumab responders, 25% placebo responders, P = .0182; 7‐point MG‐ADL improvement: 34% eculizumab responders, 10% placebo responders, P = .0007).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Currently, there is no publicly available regulatory guidance from the FDA on an appropriate MG‐ADL responder threshold, although the FDA label for eculizumab refers to REGAIN study results using a 3‐point improvement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Expert criticism of the MG-ADL as a phase 3 primary endpoint
“Although important to measure, the MG-Activities of Daily Living (MG-ADL) was thought not to assess the breadth of relevant daily activities.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As such, the MG-ADL score was considered “not appropriate” as a primary endpoint for phase 3 trials and was considered “a bar too low” for approval of a therapy, especially given the threshold of a 2-point improvement for clinically meaningful improvement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment of approximately 100 participants: company statement, March 2026
Actual registry enrollment, September 2026 record
Estimated registry enrollment, March 2026 record, superseded in August 2026
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
- AURORA has reported no efficacy or safety results. The registry record (last update posted 2026-09-01) lists the study as active and not recruiting, with estimated primary completion on 2026-12-30 and estimated study completion on 2027-09-30; record version 16 had listed estimated primary completion on 2026-11-30. The company expects a data readout in the first quarter of 2027.
- Enrollment differs by source: the company states approximately 100 participants, registry record version 16 listed an estimated enrollment of 100, and the current registry record lists an actual enrollment of 128.
- The primary endpoint is the proportion of participants with an MG-ADL improvement of 3 points or more at month 4 compared with placebo. The registry lists a crossover assignment model, a double-blind Part 1 of about 6 months, and an open-label Part 2 of about 8 months for eligible participants, and the company trial schema shows optional Descartes-08 infusions with follow-up at months 5, 6, 9, and 12.
- The phase 2b report stated plans to use the MGC score as the primary outcome in a subsequent phase 3 trial; in AURORA, MGC improvement of 4 points or more at month 4 is a secondary endpoint. One publication reports that the MG-ADL score was considered “a bar too low” for approval of a therapy given the 2-point threshold for clinically meaningful improvement. Another reports that a 3-point MG-ADL change had a specificity of 90% and a sensitivity of 62%, that no publicly available FDA guidance on an MG-ADL responder threshold exists, and that the eculizumab label refers to REGAIN results using a 3-point improvement.
- Eligibility is limited to adults with an anti-AChR antibody titer or anti-AChR cluster antibody above the reference upper normal limit, MGFA class 2 to 4, and an MG-ADL total score of 6 or more. Participants diagnosed within 12 months of screening, those with no history of systemic gMG treatment other than acetylcholinesterase inhibitors, those treated with rituximab or ocrelizumab within 12 months, and those with prior BCMA-directed therapy are excluded. In the phase 2b mITT population, 6 participants (23.1%) were triple seronegative and 1 (3.8%) was LRP4 autoantibody-positive.
- The company's Form 10-K states that a trial conducted under a Special Protocol Assessment agreement that meets its endpoints carries no guarantee that the FDA will accept or approve a marketing application.